Combination treatment for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs for ovarian cancer that has come back after responding to platinum chemotherapy. The goal is to see if adding these drugs helps control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 75 years old.
- You have recurrent ovarian cancer (not mucinous type) that has returned at least 6 months after finishing platinum chemotherapy.
- Your cancer is not suitable for surgery, and you have at least one measurable tumor.
- You are in good overall health (able to do light activity) and have adequate organ function.
- If you have not been tested for BRCA gene mutations, you agree to provide a tumor or blood sample for testing.
- You have not been treated with olaparib before, and you have not had certain immunotherapy treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
This trial tests a combination of four drugs for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this new combination can shrink tumors or slow the disease.
This study tests a combination of two drugs — a chemotherapy called liposomal irinotecan and an immunotherapy drug called enlonstobart — for women whose ovarian cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.